Skip to main content
Erschienen in: Der Onkologe 1/2013

01.01.2013 | Leitthema

CUP-Syndrom

Epidemiologie, Prognosegruppen und therapeutische Strategie

verfasst von: Dr. G. Hübner

Erschienen in: Die Onkologie | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das CUP-Syndrom („cancer of unknown primary“, Krebserkrankung mit unbekanntem Primärtumor) ist eine häufige und heterogene Erkrankung mit einem breiten Spektrum an Manifestationsformen. Sie ist eine der 10 häufigsten Tumorerkrankungen mit hoher Mortalität. Sehr variabel ist auch die Prognose – vom Langzeitüberleben bis hin zu einer kurzen Überlebenswahrscheinlichkeit von wenigen Wochen. Klar definierte Prognosegruppen sind international anerkannt. Die Kenntnis dieser Gruppen ist wegweisend für die Auswahl der bestmöglichen Therapie. Etwa 15–20% der Patienten fallen in eine der günstigen Prognosegruppen mit jeweils klarem Therapiekonzept. Die übrigen Patienten weisen ein ungünstiges Risikoprofil auf und bedürfen einer evidenzbasierten empirischen Chemotherapie oder der Behandlung innerhalb einer Studie. Die klassische Behandlung nach der Arbeitsdiagnose („best guess“) ist nicht mehr zeitgemäß und sollte einer an den Prognosegruppen ausgerichteten therapeutischen Strategie weichen.
Literatur
1.
Zurück zum Zitat Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272–1280PubMed Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272–1280PubMed
2.
Zurück zum Zitat Batsakis JG (1981) The pathology of head and neck tumors: the occult primary and metastases to the head and neck. Head Neck Surg 3:409–423PubMedCrossRef Batsakis JG (1981) The pathology of head and neck tumors: the occult primary and metastases to the head and neck. Head Neck Surg 3:409–423PubMedCrossRef
3.
Zurück zum Zitat Briasoulis E, Kalofonos H, Bafaloukos D et al (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II hellenic cooperative oncology group study. J Clin Oncol 18:3101–3107PubMed Briasoulis E, Kalofonos H, Bafaloukos D et al (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II hellenic cooperative oncology group study. J Clin Oncol 18:3101–3107PubMed
4.
Zurück zum Zitat Copeland EM, McBride CM (1973) Axillary metastases from unknown primary sites. Ann Surg 178:25–27PubMed Copeland EM, McBride CM (1973) Axillary metastases from unknown primary sites. Ann Surg 178:25–27PubMed
5.
Zurück zum Zitat Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683PubMedCrossRef Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683PubMedCrossRef
6.
Zurück zum Zitat Didolkar MS, Fanous N, Elias EG, Moore RH (1977) Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 186:625–630PubMedCrossRef Didolkar MS, Fanous N, Elias EG, Moore RH (1977) Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 186:625–630PubMedCrossRef
7.
Zurück zum Zitat Ellerbroek N, Holmes F, Singletary E et al (1990) Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66:1461–1467PubMedCrossRef Ellerbroek N, Holmes F, Singletary E et al (1990) Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66:1461–1467PubMedCrossRef
8.
Zurück zum Zitat Erichsen R, Jepsen P, Jacobsen J et al (2008) Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985–2004. Eur J Gastroenterol Hepatol 20:104–110PubMedCrossRef Erichsen R, Jepsen P, Jacobsen J et al (2008) Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985–2004. Eur J Gastroenterol Hepatol 20:104–110PubMedCrossRef
9.
Zurück zum Zitat Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J (2010) Prognostic factors in cancer of unknown primary site. Tumori 96:111–116PubMed Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J (2010) Prognostic factors in cancer of unknown primary site. Tumori 96:111–116PubMed
10.
Zurück zum Zitat Ferte C, Penel N, Bonneterre J, Adenis A (2010) Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology 78:87–93PubMedCrossRef Ferte C, Penel N, Bonneterre J, Adenis A (2010) Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology 78:87–93PubMedCrossRef
11.
Zurück zum Zitat Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):64–68CrossRef Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):64–68CrossRef
12.
Zurück zum Zitat Greco FA, Vaughn WK, Hainsworth JD (1986) Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104:547–553PubMed Greco FA, Vaughn WK, Hainsworth JD (1986) Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104:547–553PubMed
13.
Zurück zum Zitat Hainsworth JD, Johnson DH, Greco FA (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10:912–922PubMed Hainsworth JD, Johnson DH, Greco FA (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10:912–922PubMed
14.
Zurück zum Zitat Hainsworth JD, Schnabel CA, Erlander MG et al (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11:112–118PubMedCrossRef Hainsworth JD, Schnabel CA, Erlander MG et al (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11:112–118PubMedCrossRef
15.
Zurück zum Zitat Hemminki K, Liu H, Heminki A, Sundquist J (2012) Power and limits of modern cancer diagnostics: cancer of unknown primary. Ann Oncol 23:760–764PubMedCrossRef Hemminki K, Liu H, Heminki A, Sundquist J (2012) Power and limits of modern cancer diagnostics: cancer of unknown primary. Ann Oncol 23:760–764PubMedCrossRef
16.
Zurück zum Zitat Hess KR, Abbruzzese MC, Lenzi R et al (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403–3410PubMed Hess KR, Abbruzzese MC, Lenzi R et al (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403–3410PubMed
17.
Zurück zum Zitat Hübner G, Tamme C, Wildfang I et al (1990) Management of patients with carcinoma of unknown primary (CUP-Syndrome). J Cancer Res Clin Oncol 116:190CrossRef Hübner G, Tamme C, Wildfang I et al (1990) Management of patients with carcinoma of unknown primary (CUP-Syndrome). J Cancer Res Clin Oncol 116:190CrossRef
18.
Zurück zum Zitat Jackson B, Scott Conner C, Moulder J (1995) Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 61:431–434PubMed Jackson B, Scott Conner C, Moulder J (1995) Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 61:431–434PubMed
19.
Zurück zum Zitat Jesse RH, Perez CA, Fletcher GH (1973) Cervical lymph node metastasis: unknown primary cancer. Cancer 31:854–859PubMedCrossRef Jesse RH, Perez CA, Fletcher GH (1973) Cervical lymph node metastasis: unknown primary cancer. Cancer 31:854–859PubMedCrossRef
20.
Zurück zum Zitat Lefèbvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A (1990) Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg 160:443–446PubMedCrossRef Lefèbvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A (1990) Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg 160:443–446PubMedCrossRef
21.
Zurück zum Zitat Liu H, Hemminki K, Sundquist J et al (2012) Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up. Eur J Cancer Prev (epub ahead of print) Liu H, Hemminki K, Sundquist J et al (2012) Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up. Eur J Cancer Prev (epub ahead of print)
22.
Zurück zum Zitat Luke C, Koczwara B, Karapetis C et al (2008) Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health 32:383–389PubMedCrossRef Luke C, Koczwara B, Karapetis C et al (2008) Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health 32:383–389PubMedCrossRef
23.
Zurück zum Zitat Martin H, Morfit HM (1944) Cervical lymph node metastasis as the first symptom of cancer. Surg Gynecol Obstet 78:133–159 Martin H, Morfit HM (1944) Cervical lymph node metastasis as the first symptom of cancer. Surg Gynecol Obstet 78:133–159
25.
Zurück zum Zitat Nystrom SJ, Hornberger JC, Varadhachary GR et al (2012) Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget 3(6):620–628PubMed Nystrom SJ, Hornberger JC, Varadhachary GR et al (2012) Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget 3(6):620–628PubMed
26.
Zurück zum Zitat Pavlidis N (2007) Forty years experience of treating cancer of unknown primary. Acta Oncol 46:592–601PubMedCrossRef Pavlidis N (2007) Forty years experience of treating cancer of unknown primary. Acta Oncol 46:592–601PubMedCrossRef
27.
28.
Zurück zum Zitat Penel N, Negrier S, Ray-Coquard I et al (2009) Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One 4:e6483PubMedCrossRef Penel N, Negrier S, Ray-Coquard I et al (2009) Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One 4:e6483PubMedCrossRef
29.
Zurück zum Zitat Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43:2026–2036PubMedCrossRef Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43:2026–2036PubMedCrossRef
30.
Zurück zum Zitat Ponce LJ, Segura HA, Diaz BR et al (2007) Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 9:452–458CrossRef Ponce LJ, Segura HA, Diaz BR et al (2007) Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 9:452–458CrossRef
31.
Zurück zum Zitat Randen M, Lewin F, Helde FM et al (2008) Cancer with unknown primary–implementation of a regional referral process and clinical practice guidelines. Clin Oncol (R Coll Radiol) 20:564 Randen M, Lewin F, Helde FM et al (2008) Cancer with unknown primary–implementation of a regional referral process and clinical practice guidelines. Clin Oncol (R Coll Radiol) 20:564
32.
Zurück zum Zitat Randen M, Rutqvist LE, Johansson H (2009) Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol 48:915–920PubMedCrossRef Randen M, Rutqvist LE, Johansson H (2009) Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol 48:915–920PubMedCrossRef
33.
Zurück zum Zitat Richardson RL, Schoumacher RA, Fer MF et al (1981) The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med 94:181–186PubMed Richardson RL, Schoumacher RA, Fer MF et al (1981) The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med 94:181–186PubMed
34.
Zurück zum Zitat Rosen PP, Kimmel M (1990) Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol 21:518–523PubMedCrossRef Rosen PP, Kimmel M (1990) Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol 21:518–523PubMedCrossRef
35.
Zurück zum Zitat Seve P, Sawyer M, Hanson J et al (2006) The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 106:2058–2066PubMedCrossRef Seve P, Sawyer M, Hanson J et al (2006) The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 106:2058–2066PubMedCrossRef
36.
Zurück zum Zitat Shu X, Liu H, Ji J et al (2012) Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights? Ann Oncol 23:269–275PubMedCrossRef Shu X, Liu H, Ji J et al (2012) Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights? Ann Oncol 23:269–275PubMedCrossRef
37.
Zurück zum Zitat Shu X, Sundquist K, Sundquist J, Hemminki K (2012) Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 21:281–288PubMedCrossRef Shu X, Sundquist K, Sundquist J, Hemminki K (2012) Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 21:281–288PubMedCrossRef
38.
Zurück zum Zitat Strnad CM, Grosh WW, Baxter J et al (1989) Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111:213–217PubMed Strnad CM, Grosh WW, Baxter J et al (1989) Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111:213–217PubMed
39.
Zurück zum Zitat Taylor MB, Bromham NR, Arnold SE (2012) Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol 85:661–671PubMedCrossRef Taylor MB, Bromham NR, Arnold SE (2012) Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol 85:661–671PubMedCrossRef
40.
Zurück zum Zitat van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF (2002) Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 38:409–413CrossRef van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF (2002) Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 38:409–413CrossRef
41.
Zurück zum Zitat Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9:596–599PubMedCrossRef Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9:596–599PubMedCrossRef
Metadaten
Titel
CUP-Syndrom
Epidemiologie, Prognosegruppen und therapeutische Strategie
verfasst von
Dr. G. Hübner
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 1/2013
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-012-2312-0

Weitere Artikel der Ausgabe 1/2013

Der Onkologe 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.